Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year [Yahoo! Finance]
Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year
Sanuwave Health (SNWV) was downgraded by Zacks Research from "hold" to "strong sell".
Sanuwave Health (SNWV) had its "buy" rating reaffirmed by Roth Mkm. They now have a $47.00 price target on the stock, down from $53.00.
How The Reset Price Target Is Rewriting The Story For SANUWAVE Health (SNWV) [Yahoo! Finance]